07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

GastroPanel regulatory update

Biohit said Chinese health associations The Chinese Society of Digestive Endoscopy and The Society of Ontological Endoscopy of Chinese Anti-Cancer Association issued a consensus clause recommending serum screening with Pepsinogen I and II, Gastrin-17 and...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Biohit, Anhui Wisdom-Win Investment Co. Ltd. deal

Biohit and Anhui Wisdom-Win formed a JV, Biohit Biotech (Hefei) Co. Ltd. (Hefei, China), to manufacture and commercialize Biohit's GastroPanel kits in China. Biohit will own 40% of the newco, while Anhui Wisdom-Win will own...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

Biohit, IBL International GmbH sales and marketing update

Biohit Oyj (HSE:BIOBV), Helsinki, Finland   IBL International GmbH , Hamburg, Germany   Business: Diagnostic   Biohit granted IBL exclusive rights to distribute Biohit's GastroPanel in Germany. Biohit says the non-invasive blood test can diagnose...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Biohit, Euroclone S.p.A. deal

Diagnostic company Biohit acquired Euroclone's Euroclone Gastro s.r.l. gastrointestinal diagnostics subsidiary for 180,000 new Biohit shares, or about €1.1 million ($1.5 million) based on Biohit's close of €6.26 on April 17, the day before the...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

GastroPanel regulatory update

Biohit Oyj (HSE:BIOBV), Helsinki, Finland   Product: GastroPanel   Business: Gastrointestinal   Biohit said a report of the European Helicobacter Pylori Study Group recommends blood sample biomarker tests to diagnosis disease of the stomach mucosa...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

GastroPanel regulatory update

Biohit said FDA has delayed a decision and requested clarifications on a 510 (k) application for its Pepsinogen I and II ELISA assays to test for corpus atrophy. The company, which plans to include the...